- Home
- FLX vs CRGX Comparison
FLX vs CRGX Comparison
Compare FLX & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLX
- CRGX
- Stock Information
- Founded
- FLX 2013
- CRGX 2021
- Country
- FLX China
- CRGX United States
- Employees
- FLX N/A
- CRGX N/A
- Industry
- FLX
- CRGX
- Sector
- FLX
- CRGX
- Exchange
- FLX NYSE
- CRGX Nasdaq
- Market Cap
- FLX N/A
- CRGX 190.0M
- IPO Year
- FLX 2024
- CRGX 2023
- Fundamental
- Price
- FLX $3.32
- CRGX $4.59
- Analyst Decision
- FLX
- CRGX Hold
- Analyst Count
- FLX 0
- CRGX 7
- Target Price
- FLX N/A
- CRGX $5.33
- AVG Volume (30 Days)
- FLX 86.7K
- CRGX 1.9M
- Earning Date
- FLX 08-27-2025
- CRGX 08-11-2025
- Dividend Yield
- FLX N/A
- CRGX N/A
- EPS Growth
- FLX N/A
- CRGX N/A
- EPS
- FLX N/A
- CRGX N/A
- Revenue
- FLX $595,490,250.00
- CRGX N/A
- Revenue This Year
- FLX N/A
- CRGX $57.81
- Revenue Next Year
- FLX N/A
- CRGX N/A
- P/E Ratio
- FLX N/A
- CRGX N/A
- Revenue Growth
- FLX N/A
- CRGX N/A
- 52 Week Low
- FLX $2.01
- CRGX $3.00
- 52 Week High
- FLX $21.95
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- FLX N/A
- CRGX 61.56
- Support Level
- FLX N/A
- CRGX $4.32
- Resistance Level
- FLX N/A
- CRGX $4.63
- Average True Range (ATR)
- FLX 0.00
- CRGX 0.16
- MACD
- FLX 0.00
- CRGX 0.04
- Stochastic Oscillator
- FLX 0.00
- CRGX 76.44
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.